ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2008;86:1055-1056. doi:10.1016/j.athoracsur.2007.10.022
© 2008 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Suvitesh Luthra
Sanjay Theodore
James Tatoulis
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Luthra, S.
Right arrow Articles by Tatoulis, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luthra, S.
Right arrow Articles by Tatoulis, J.
Related Collections
Right arrow Cardiac - other
Right arrowRelated Article

Correspondence

Bioglue: A Word of Caution

Suvitesh Luthra, MS, MRCS-Ed, Sanjay Theodore, MS, MCh(CTVS), James Tatoulis, MS, FRACS

Department of Cardiothoracic Surgery, Royal Melbourne Hospital, University of Melbourne, 2 North Grattan St, Parkville, Melbourne, Victoria 3050, Australia

(Email: suviteshluthra@yahoo.com).

The first 20% of the full text of this article appears below.

To the Editor:

We read with interest the article by Zehr and colleagues [1] that describes the use of albumin-glutaraldehyde glue in cardiac surgery.

Our experience with Bioglue (bovine serum albumin [BSA] 25% and glutaraldehyde 10%, Cryolife Inc, Kennesaw, GA) extends to uses in aortic suture lines, lung surgery, and occasionally securing hemostasis in very thin-walled atria. Earlier we had described its use in pericardial patch reinforcement of a drug-eluting stent induced coronary aneurysm [2].

The two components of Bioglue (Cryolife, Inc) can have a number of additional potential adverse consequences that have not been listed by the authors:

1 Primary hypersensitivity and allergy to the components.
2 Immune response on repeat application in persons in whom it has been previously used.
. . . [Full Text of this Article]


Related Article

Reply
Kenton J. Zehr
Ann. Thorac. Surg. 2008 86: 1056-1057. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
K. J. Zehr
Reply.
Ann. Thorac. Surg., September 1, 2008; 86(3): 1056 - 1057.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The Society of Thoracic Surgeons.